Description
Your oncologist (cancer doctor) may prescribe Mektovi for managing unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Metastatic melanoma is a type of skin cancer. Mektovi is only for use in combination with encorafenib.
Functioning as a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activity, Mektovi curbs the growth of cancer cells by preventing the action of these proteins.
Fact Table |
Formula |
C17H15BrF2N4O3 |
License |
US FDA, EMA |
Bioavailability |
~50% |
Legal status |
Prescription only (?) |
Chemical Name |
(3S)-3-{[(2S)-2-(4-bromo-2-fluorophenyl)-2-(3,3-difluorocyclobutyl)acetyl]amino}-3-methylbutanoic acid |
Elimination half-life |
3.5 hours |
Dosage (Strength) |
15 mg tablets |
Pregnancy |
Not recommended |
Brands |
Mektovi |
Protein binding |
97% |
PubChem CID |
135565536 |
MedlinePlus |
a618014 |
ChEBI |
134723 |
ATC code |
L01XE56 |
DrugBank |
DB11995 |
KEGG |
D10835 |
Routes of administration |
Oral |
Directions
The recommended dosage entails taking 45 mg orally twice daily in conjunction with encorafenib. Mektovi can be ingested with or without food.
Patients with a history of liver disease should inform their doctor, as a dosage adjustment to 30 mg twice daily may be necessary.
It is imperative not to cease or alter the Mektovi dosage without consulting your doctor.
Ingredients
The active ingredient in Mektovi is binimetinib.
Interactions
There are no significant drug-drug interactions between Mektovi and other medications.
Cautions
Patients commencing treatment with a history of heart disease should inform their doctor. Heart function assessments are advisable before starting treatment, after one month, and subsequently every 2-3 months.
It is crucial to disclose any history of clotting disorders. Caution is warranted for individuals with a history of eye, lung, liver, musculoskeletal, or bleeding disorders.
Pregnant or individuals planning on becoming pregnant should not take Mektovi.
Side Effects
Common adverse reactions include:
- Abdominal pain
- Bleeding from anus
- Bleeding hemorrhoids
- Cancer
- Cardiomyopathy
- Central serous chorioretinopathy
- Cough (Non-small cell lung cancer)
- Diarrhea
- Dyspnea (Non-small cell lung cancer)
- Fatigue
- Hemothorax
- Hematochezia
- Hemorrhage
- Intracranial hemorrhage, Fatal
- Left ventricular cardiac dysfunction
- Musculoskeletal pain (Non-small cell lung cancer)
- Nausea
- Papilloma (Non-small cell lung cancer)
- Pulmonary embolism
- Rectal hemorrhage
- Squamous cell carcinoma of the skin (Non-small cell lung cancer)
- Thrombosis of retinal vein
- Uveitis
- Vomiting
- Venous thromboembolism
References
- Mektovi [package insert]. Boulder, CO: Array BioPharma; June 2018.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14577